Methyl-CpG Binding Protein 2 in Alzheimer Dementia

Baeksun Kim1,2, Yunjung Choi3,4, Hye-Sun Kim3,4, Heh-In Im1,2,5

1Convergence Research Center for Diagnosis, Treatment and Care System of Dementia (DTC), Korea Institute of Science and Technology (KIST), Seoul, Korea
2Division of Bio-Medical Science and Technology, KIST School, Korea University of Science and Technology (UST), Seoul, Korea
3Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea
4Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea
5Center for Neuroscience, Korea Institute of Science and Technology (KIST), Seoul, Korea

Despite decades of research on Alzheimer disease, understanding the complexity of the genetic and molecular interactions involved in its pathogenesis remains far from our grasp. Methyl-CpG Binding Protein 2 (MeCP2) is an important epigenetic regulator enriched in the brain, and recent findings have implicated MeCP2 as a crucial player in Alzheimer disease. Here, we provide comprehensive insights into the pathophysiological roles of MeCP2 in Alzheimer disease. In particular, we focus on how the alteration of MeCP2 expression can impact Alzheimer disease through risk genes, amyloid-β and tau pathology, cell death and neurodegeneration, and cellular senescence. We suggest that Alzheimer disease can be adversely affected by upregulated MeCP2-dependent repression of risk genes (MEF2C, ADAM10, and PM20D1), increased tau accumulation, and neurodegeneration through neuronal cell death (excitotoxicity and apoptosis). In addition, we propose that the progression of Alzheimer disease could be caused by reduced MeCP2-mediated enhancement of astrocytic and microglial senescence and consequent glial SASP (senescence-associated secretory phenotype)-dependent neuroinflammation. We surmise that any imbalance in MeCP2 function would accelerate or cause Alzheimer disease pathogenesis, implying that MeCP2 may be a potential drug target for the treatment and prevention of Alzheimer disease.

Keywords: MeCP2; Alzheimer disease; Risk genes; Neurodegeneration; Senescence; Neuroinflammation

ALZHEIMER DISEASE

Alzheimer disease is a neurodegenerative disease that constitutes the most common form of dementia without a cure. Alzheimer’s Association Reports projected that the social and economic burden and the global prevalence of Alzheimer disease will grow constantly until 2050 [1], demanding immediate attention to research on the treatment and prevention of Alzheimer disease. The pathogenesis of Alzheimer disease is defined by the neurotoxic accumulation of extracellular amyloid-β plaques and intracellular tau neurofibrillary tangles, glial scarring and gliosis, and aberrant alterations in synaptic plasticity, ultimately resulting in severe cognitive impairments and extensive neuronal loss [2]. The cognitive dysfunctions observed in Alzheimer disease primarily consist of memory loss and problems in language or thinking skills.

Among the diverse causes of Alzheimer disease identified to date, the foremost studies have revealed that Alzheimer disease...
can arise from familial or sporadic mutations in a number of risk genes, most notably amyloid precursor protein (APP), presenilin-1 or -2 (PSEN1, PSEN2), β-secretase 1 (BACE1), and apolipoprotein E (APOE) [3]. Research on these risk genes mainly revolved around the amyloid hypothesis, positing that dysfunction in the processing of amyloid-β protein — more specifically, the imbalance between production and clearance of amyloid-β peptides such as amyloid-β-42 — is the essential cause of Alzheimer disease [2]. However, recent failures of amyloid-β monoclonal antibodies in clinical trials warrant the identification of new genetic and molecular targets for the treatment and prevention of Alzheimer disease [4,5]. For instance, recent efforts from large-cohort genome-wide association studies (GWAS) have discovered a number of novel risk genes for Alzheimer disease [6,7] and researchers are bringing tau pathology into the spotlight in Alzheimer disease research [8,9].

Notably, mounting evidence and recent breakthroughs have highlighted neuroinflammation as a critical part of the pathogenesis of Alzheimer disease [10,11]. Pathological neuroinflammation in Alzheimer disease is principally initiated by amyloid-β-dependent, tau-dependent, or idiopathic long-lasting activation of microglia, the proficient innate immune cells in the central nervous system. Subsequently, the sustained release of proinflammatory and neurotoxic mediators leads to an increased emergence of reactive astrocytes and abnormal accumulation of oxidative stress in the brain, ultimately rendering the brain microenvironment inhospitable to neurons. Neuroinflammation is therefore thought to be a central factor underlying the process of neurodegeneration in Alzheimer disease [12].

It is also important to note that a potential contributor to neuroinflammation in the aging brain is cellular senescence, which is apt to develop in replication-competent glial cells [13]. Cellular senescence is characterized by irreversible cell cycle arrest, resistance to apoptosis, and the senescence-associated secretory phenotype (SASP). Interestingly, the SASP converts senescent brain cells into a pro-inflammatory phenotype that releases cytokines, chemokines, proteases, and growth factors [14], which in turn can activate neighboring microglia and astrocytes to give rise to reactive glia. Through this mechanism, cellular senescence can prompt neuroinflammation in the brain through both reactive glia and senescent glia. In addition, recent evidence has demonstrated that the accumulation of senescent glial cells is critical for the manifestation of Alzheimer disease phenotypes, including neurodegeneration and cognitive decline [15,16]. These findings jointly suggest that cellular senescence may be the cellular intermediary connecting molecular pathology to the behavioral phenotype of Alzheimer disease.

METHYL-CpG BINDING PROTEIN 2

Methyl-CpG binding protein 2 (MeCP2) is a chromosomal protein that recognizes and binds to methylated CpG nucleotide sequences to control transcription via epigenetic modulation. The main modes of transcriptional regulation by MeCP2 include histone deacetylase-dependent histone deacetylation, bridging histone methylation and DNA methylation, and CREB1-dependent transcriptional activation [17-20]. MeCP2 is known to be critical for the normal functioning of the nervous system, as it can selectively repress the expression of the BDNF gene [21,22] and shape multiple aspects of excitatory and inhibitory neurotransmission in diverse manners [23-25]. In addition, deficient MeCP2 functioning leads to impaired neuronal maturation in the brain [26,27] and the X-linked progressive neurodevelopmental disorder Rett syndrome, which is characterized by severe mental retardation and autistic features, mainly in females [28,29].

Interestingly, a study revealed that hippocampal MeCP2 was upregulated in Alzheimer disease patients [30], but another study showed that MeCP2 expression was reduced in the hippocampus of APP/PS1 mice and that upregulation of hippocampal MeCP2 could play a therapeutic role in an Alzheimer disease mouse model [31]. These data demonstrate that there exists an interaction between Alzheimer disease and MeCP2, which requires an in-depth investigation. This mini-review aims to identify the common functional traits between MeCP2 and biological factors of Alzheimer disease, and to summarize findings from recent studies in order to propose hypotheses regarding the pathophysiological roles of MeCP2 in Alzheimer disease. Specifically, we focus on the interactions of MeCP2 with Alzheimer disease risk genes and amyloid-β and tau pathology, as well as the MeCP2-dependent regulation of neuronal cell death and cellular senescence.

MeCP2 AND ALZHEIMER DISEASE RISK GENES

In the past decades, genetic association studies have revealed a multitude of risk genes for Alzheimer disease, but only a handful can be linked to MeCP2. The MeCP2-linked Alzheimer disease risk genes include MEF2C, ADAM10, and PM20D1.
MeCP2 Represses MEF2C

MEF2C encodes a transcriptional factor (myocyte enhancer factor 2C; Mef2c) that is involved in cardiac, vascular, and neuronal development [32-34]. In the brain, MEF2C plays a critical role by regulating neurogenesis, neuronal survival, and synaptic plasticity [35,36]. Mutations in MEF2C lead to neurodevelopmental disabilities including severe mental retardation [37]. In the largest GWAS of late-onset Alzheimer disease (LOAD) to date [6,7], MEF2C has been identified as a potential risk gene for Alzheimer disease, but the pathophysiological role of MEF2C in Alzheimer disease remains unclear.

MeCP2 binds to the promoter region of the MEF2C gene and represses Mef2c expression in the mouse brain and human-derived cells [20,38]. Since MeCP2 expression is elevated in the brain of individuals with Alzheimer disease and MEF2C dysfunction leads to mental retardation, MeCP2-mediated repression of Mef2c could contribute to cognitive decline in Alzheimer disease.

MeCP2 Represses ADAM10

ADAM10, which encodes ADAM metallopeptidase domain 10, is responsible for the proteolytic cleavage of a number of cell-surface proteins. Notably, the product of ADAM10 functions as an α-secretase involved in cleaving the ectodomain of amyloid precursor protein (APP) [39]. Rare variants of ADAM10 have been found to cosegregate in families affected by LOAD [40,41]. In addition, the largest GWAS of LOAD have identified ADAM10 as a risk gene for Alzheimer disease [6,7]. ADAM10 variants can increase amyloid-β levels in vitro [40], and have been found to induce amyloidogenic cleavage and increase the amyloid-β plaque load in an Alzheimer disease mouse model [41]. However, APP cleavage by wild-type α-secretase is thought to be neuroprotective in Alzheimer disease since wild-type α-secretase cleaves a site within the amyloid-β sequence to prevent the overall production of amyloid-β [42].

A recent study demonstrated that MeCP2 inhibited ADAM10 expression in mouse neural progenitor cells and human-derived cells [43]. Since Alzheimer disease patients could carry rare variants of ADAM10, MeCP2-dependent inhibition of ADAM10 could disrupt the activity of mutant α-secretase, thereby reducing amyloid-β deposition in the brain in Alzheimer disease patients. However, MeCP2-dependent inhibition of ADAM10 could also increase the amyloid-β load in Alzheimer disease patients who retain wild-type ADAM10.

MeCP2 Represses PM20D1

The product of peptidase M20 domain containing 1 (PM20D1) is a circulating biosynthetic enzyme that catalyzes the condensation of fatty acids and a number of amino acids to produce N-acyl amino acids [44]. Increased levels of PM20D1 promote energy expenditure in vivo. However, the role of PM20D1 in neurons and in the brain remains unclear. A methylated quantitative trait locus study revealed that PM20D1 was the sole risk gene with consistently enriched promoter hypermethylation in Alzheimer disease patients [45]. Moreover, PM20D1 levels increased after neurotoxic insults in an APP/PS1 mouse model and human Alzheimer disease patients, and PM20D1 was shown to protect neurons against the insults. Increasing or decreasing PM20D1 expression reduces or aggravates Alzheimer disease pathology, respectively. These data suggest that PM20D1 plays a neuroprotective role against Alzheimer disease.

Interestingly, increased binding of MeCP2 to the PM20D1 promoter was observed in immortalized B cells from Alzheimer disease patients with the methylated rs708727-rs960603 haplotype, and the MeCP2-bound promoter of PM20D1 showed decreased histone acetylation [45]. These data suggest that MeCP2 inhibits PM20D1 via induction of a transcriptionally silent chromatin state. Thus, MeCP2-PM20D1 interactions could render the brain susceptible to neurodegeneration and cognitive decline in response to neurotoxic mediators of Alzheimer disease pathology.

MeCP2 Is Unlikely to Be Linked With PSEN and BACE1

PSEN1 and PSEN2 encode presenilin-1 and presenilin-2, which form the core catalytic subunit of γ-secretase, whereas BACE1 encodes β-secretase [42]. The γ- and β-secretases sequentially cleave APP to produce amyloid-β. Mutations in PSEN genes can cause incomplete digestion of amyloid-β, which leads to enhanced amyloid-β-42 production, and could also lead to a loss of other essential presenilin functions and trigger the cellular and behavioral impairments found in Alzheimer disease.

The links between MeCP2 and the PSEN genes and BACE1 are weak. MeCP2 expression was not correlated with the PSEN1 or PSEN2 expression profile in the developing cerebral cortex of wild-type mice [46]. Mice with MeCP2 ablation under transverse aortic constriction exhibited enrichment of the PSEN pathway in a bioinformatics analysis [47], but the lack of more direct evidence precludes further interpretation. In addition, BACE1 knockdown did not affect MeCP2 expression in human-derived cells [48]. These data indicate that the PSEN...
In the hippocampal CA1 of amyloid-β-injected rats [49]. In addition, MeCP2 siRNA treatment restored hippocampal dendritic spine numbers and memory deficits in a Morris water maze in amyloid-β-injected rats. However, amyloid-β was shown to reduce MeCP2 expression in immortalized hippocampal neurons and in the hippocampus of APP/PS1 mice [31], in contrast with the above finding. In addition, MeCP2 deficiency did not alter the level of APP in the cortex, although it disturbed the localization of APP to the cell membrane [50].

**MeCP2 Controls Tau Pathology and Vice Versa**

In a transgenic mouse model of tauopathy overexpressing the human tau gene, whole genome expression analysis revealed that both total and phosphorylated MeCP2 were upregulated in the hippocampus [51]. Total MeCP2 levels were also upregulated in the cortex and cultured cortical neurons from the tauopathy mouse model. Importantly, human Alzheimer disease brain tissue also exhibited elevated levels of total and phosphorylated MeCP2, which is consistent with the findings from the tauopathy mice model. Furthermore, mice with MeCP2 triplication syndrome displayed elevated tau expression within the hippocampus and cortex, followed by neuronal loss in these brain regions [52]. Cognitive impairment was also evident in Y-maze and novel object recognition tests.

*In vitro*, MeCP2 knockdown in a human tau-expressing neuronal cell line also resulted in significantly decreased levels of total and phosphorylated tau [51].

**MeCP2 and the Pathology of Alzheimer Disease: Summary**

The equivocal findings in the literature suggest that the link between MeCP2 and amyloid-β remains unclear. Nonetheless, increased levels of tau consistently resulted in both the overexpression and activation of MeCP2, and alterations in MeCP2 expression were positively correlated with tau levels in neurons. From these data, a critical connection between MeCP2 and Alzheimer disease tau pathology is apparent. In the future, more in-depth studies are needed to reveal the causal relationship and modes of interaction between MeCP2 and tau pathology.

**MeCP2 AND NEURONAL CELL DEATH: APOPTOSIS, EXCITOTOXICITY, AND NEURODEGENERATION**

MeCP2 is involved in the regulation of neuronal cell death by apoptosis and excitotoxicity. Although the precise mechanism
underlying neurodegeneration in Alzheimer disease is unclear, studies have demonstrated that in Alzheimer disease, the brain is afflicted by increased excitotoxic and apoptotic cell death [53,54], suggesting that both excitotoxicity and apoptosis can contribute to the neurodegenerative process in Alzheimer disease. In this instance, alteration in MeCP2 expression may directly mediate neurodegeneration through excitotoxicity and apoptosis.

**Increased MeCP2 Dosage Leads to Excitotoxicity and Apoptosis**

In cultured neurons and neuronal tissue, MeCP2 overexpression increases apoptotic cell death [55,56] (but also see [57]). MeCP2 overexpression-dependent apoptosis could arise from excitotoxicity mediated by astrocytic glutamate release [52]. More importantly, an increase in the MeCP2-e2 isoform was found to mediate amyloid-β-induced apoptosis in cultured cortical neurons [58], demonstrating the potential significance of MeCP2 for neurodegeneration in Alzheimer disease.

In vivo, a human MeCP2-e2 isoform gain-of-function mutation promoted apoptosis in Drosophila motor neurons [59]. In addition, MeCP2 overexpression led to neuronal loss in the hippocampus, cortex, and cerebellum in a MeCP2 triplication syndrome mouse model [52].

**Decreased MeCP2 Dosage Facilitates Cell Death**

In cultured neurons, MeCP2 deficiency resulted in a greater magnitude and faster onset of apoptotic cell death when the neurons were exposed to either excitotoxic or hypoxic-ischemic insults [60]. However, although microglial MeCP2 knockdown directly caused NMDA receptor-dependent excitotoxic neuronal cell death [61], astrocytic MeCP2 deficiency did not affect the rate of neuronal cell death [62].

In vivo, MeCP2 deficiency resulted in a reduced number of medullar tyrosine hydroxylase-expressing neurons, but the effect was not due to apoptosis [63], and MeCP2 deficiency had no effect on apoptotic cell death in the locus coeruleus [64,65]. However, MeCP2 deficiency increased apoptosis in immature olfactory neurons in mice at 52 weeks of age, but not at 12 weeks of age or younger [66]. In addition, degenerating dopaminergic neurons in mice exhibited reduced MeCP2 activity [67].

**MeCP2 and Neuronal Cell Death: Summary**

Increased MeCP2 expression can directly induce excitotoxicity and apoptosis, which could underlie amyloid-β-induced apoptotic neurodegeneration. In the future, research on the roles of the MeCP2-e2 isoform and astrocytic MeCP2 could lead to a broader understanding of the biological pathways underlying neurodegeneration in Alzheimer disease.

However, MeCP2 deficiency does not seem to directly impact neuronal cell death. Overall MeCP2 downregulation may just indirectly facilitate neuronal cell death by rendering neurons susceptible to cell death-triggering insults or events (e.g., excitotoxicity, hypoxia-ischemia, aging, or neurodegenerative disease), although microglial MeCP2 reduction seems to directly dysregulate neuronal cell survival through excitotoxicity. Further studies are required to clarify the link between MeCP2 deficiency and neuronal cell death.

**MeCP2 AND CELLULAR SENESCENCE**

Cellular senescence is thought to be one of the underlying causes of aging [68], promoting aging-related phenotypes [69,70] and contributing to the pathogenesis of neurodegenerative diseases including Alzheimer disease [15,16]. Interestingly, accumulating evidence indicates that MeCP2 is associated with cellular senescence, which suggests cellular senescence as a potential linker between MeCP2 and Alzheimer disease.

**The Link Between Increased MeCP2 Levels and Cellular Senescence Is Elusive**

Human embryonic lung fibroblasts undergoing senescence exhibited upregulation of MeCP2 mRNA along with increased senescence-associated β-galactosidase (SA-β-gal) activity, but chemically induced premature senescence did not change the expression of MeCP2 in these cells [71]. In addition, MeCP2 protein levels did not differ between lung fibroblasts with lower and higher degrees of senescence [72]. Moreover, MeCP2 overexpression-induced senescence in endothelial progenitor cells resulted in an increased number of apoptosis cells and cleaved caspase-3 protein levels [73], in contrast to the apoptosis-resistant characteristic of senescent cells.

**MeCP2 Downregulation Induces Cellular Senescence**

Neural progenitor cells and neurons differentiated from fibroblasts of patients with Rett syndrome displayed elevated SA-β-gal activity, p53 induction, and altered SASP signature genes [74]. Furthermore, mesenchymal stem cells from Rett syndrome patients showed a lower degree of apoptosis and were prone to senescence, which was accompanied by a reduction of
apoptosis-related genes and upregulation of senescence-promoting genes [75-77]. Furthermore, partial silencing of MeCP2 in human mesenchymal stem cells reduced apoptosis and triggered senescence [78].

**MeCP2 and Cellular Senescence: Summary**

The relationship between MeCP2 overexpression and senescence seems controversial since the results are generally equivocal. In contrast, MeCP2 downregulation was significantly associated with cellular senescence. MeCP2-silenced cells and Rett syndrome patient-derived cells consistently exhibited a senescent phenotype, alterations in senescence-related genes, and decreased apoptosis. Since cellular senescence affects the major pathology of neurodegenerative diseases, the correlation between Alzheimer disease and cellular senescence induced by MeCP2 downregulation may be worthy of further investigation.

**MeCP2 and Urological Dysfunction**

Earlier reviews of Rett Syndrome considered the aspect of its recurrent infection a quandary [79]. Mixed with symptoms of meningitis, urinary tract infections have been considered a peripheral occurrence, not deeply associated with the pathognomonic representation.

**Link between Rett syndrome and urinary dysfunction**

Earlier studies of MeCP2 and its association with the urinary tract has been limited to familial studies. As in Rett syndrome, considered to be exclusively female, the association with the *MECP2* gene has identified male cases which involve Klinefelter’s mosaic, males with severe neonatal encephalopathy in

---

**Fig. 1.** A schematic model depicting the impact of MeCP2 dysfunction in Alzheimer disease. 1-1) MeCP2 deficiency induces cellular senescence and upregulation of senescence-associated secretory phenotype (SASP) genes in glial cells (astrocytes and microglia). 1-2) Senescent glia secrete SASP molecules (cytokines, chemokines, proteases, and growth factors), which in turn directly induce neuroinflammation in neurons and give rise to reactive glia that induce excitotoxicity. 2-1) MeCP2 upregulation causes downregulation of the Alzheimer disease risk genes *MEF2C*, *ADAM10*, and *PM20D1* in neurons. 2-2) In conjunction, MeCP2 upregulation exacerbates tau pathology in neurons. 3) Taken together, MeCP2 dysfunction results in the neurodegeneration observed in Alzheimer disease. Red arrows indicate the effects exerted by MeCP2 deficiency and blue arrows indicate the effects resulting from MeCP2 upregulation.
families with Rett syndrome and males who are mosaic for the MECP2 mutation [80]. Zeev et al. [80] describes male mutation in familial Rett syndrome where it manifests as bladder and ureteral hypotonicity, resulting in early and recurrent urinary tract infections. In contrast to female involvement of predominant constipation, breathing abnormalities and cardiac arrhythmias as the manifestation of its autonomic nervous system involvement.

**MeCP2 involving peripheral neural and smooth muscle plasticity**

Recent advances have allowed review of the genetic data of Rett syndrome patients, positively identifying the association between MeCP2 and urological dysfunction [81]. Other studies have shown miR-132 and miR212 involving synaptic plasticity and cholinergic signaling affected outside the CNS, including smooth muscle, and changes in MeCP2 [82]. In this study, bladder outlet obstruction induced miR-132/212 and repressed MeCP2 and cell viability. Other studies have also shown miR-132 overexpression in bladder overactivity as well [83].

**HYPOTHESES AND CONCLUSION**

Studies have demonstrated elevated MeCP2 levels in the cortex and hippocampus of Alzheimer disease patients. Aberrantly increased MeCP2 could exacerbate Alzheimer disease through multiple mechanisms. First, the MeCP2-mediated repression of the Alzheimer disease risk genes MEF2C, ADAM10, and PM20D1 could negatively impact the progression of Alzheimer disease. Second, MeCP2 could drive the accumulation of tau protein in the brain. Lastly, MeCP2 could render neurons prone to neurodegeneration by inducing excitotoxicity and apoptosis. In the future, corroborating evidence should be sought and the underlying mechanisms should be determined to clarify the roles of increased MeCP2 in Alzheimer disease.

However, although MeCP2 levels were found to be elevated in the brain of Alzheimer disease patients, its cell type-specific expression pattern in Alzheimer disease has not been documented to date. Studies have demonstrated that MeCP2 deficiency can induce cellular senescence, while senolytic therapy — selective elimination of senescent cells — is effective against astrocyte- and microglia-induced defects in Alzheimer disease [15,16]. Synthesizing these observations, in Alzheimer disease, the brain may exhibit an abnormally large extent of astrocytic and microglial senescence, potentially due to MeCP2 downregulation in the glia, which in turn can accelerate neuronal dysfunction and neurodegeneration in Alzheimer disease through glial SASP. Future studies should elucidate the cell type-specific expression and functions of MeCP2 in brain tissue affected by Alzheimer disease, along with the pathophysiological roles of reduced MeCP2 in Alzheimer disease-associated senescence.

Integrating the data handled in this review, we suggest a model in which Alzheimer disease pathogenesis could be exacerbated by MeCP2 dysfunction (Fig. 1). MeCP2 upregulation could dysregulate Alzheimer risk genes and accelerate tau pathology, while MeCP2 deficiency could induce glial senescence that contributes to neuroinflammation and excitotoxicity in Alzheimer disease. In both pathways, MeCP2 dysfunction-induced neuronal cell death and neurodegeneration play a major role.

Research from the recent decade has suggested that MeCP2 could play a multifaceted role in Alzheimer disease. From the mounting evidence, we propose that MeCP2 can repress Alzheimer disease risk genes, prevent the aggravation of tau pathology, and inhibit the induction of neuronal cell death and cellular senescence. Further studies of the genetic and molecular mechanisms underlying the impact of MeCP2 on Alzheimer disease should follow in order to reveal the therapeutic potential of MeCP2 as a drug target for Alzheimer disease and provide novel insights into the pathogenesis of Alzheimer disease.

**AUTHOR CONTRIBUTION STATEMENT**

- Full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis: BK, HII
- Study concept and design: BK, YC, HII
- Acquisition of data: BK, YC
- Analysis and interpretation of data: BK, YC
- Drafting of the manuscript: BK, YC
- Critical revision of the manuscript for important intellectual content: BK, YC
- Statistical analysis: BK, YC
- Obtained funding: HII
- Administrative, technical, or material support: HSK
- Study supervision: HII

**REFERENCES**

1. Alzheimer’s Association. 2019 Alzheimer’s disease facts and figures. Alzheimers Dement 2019;15:321-87.
2. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease
at 25 years. EMBO Mol Med 2016;8:595-608.
3. Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 2015;77:43-51.
4. Makin S. The amyloid hypothesis on trial. Nature 2018;559:54-7.
5. Mullard A. Anti-amyloid failures stack up as Alzheimer antibody flops. Nat Rev Drug Discov 2019 Apr 5 [Epub]. https://doi.org/10.1038/d41573-019-00064-1.
6. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013;45:1452-8.
7. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet 2019;51:414-30.
8. Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neuro 2018;18:439-415.
9. Villemagne VL, Dore V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol 2018;14:225-36.
10. Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015;14:388-405.
11. Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer's disease. Nat Immunol 2015;16:229-36.
12. Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science 2016;353:777-83.
13. Chinta SJ, Woods G, Rane A, Demaria M, Campisi J, Andersen JK. Cellular senescence and the aging brain. Exp Gerontol 2015;68:3-7.
14. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008;6:2853-68.
15. Bussian TJ, Aziz A, Meyer CE, Swenson BL, van Deursen JM, Baker DJ. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 2018;562:578-82.
16. Zhang P, Kishimoto Y, Grammatikakis I, Gottimukkala K, Cutler RG, Zhang S, et al. Senolytic therapy alleviates Abeta-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer's disease model. Nat Neurosci 2019;22:719-28.
17. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-91.
18. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-9.
19. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003;278:4035-40.
20. Chahroum M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008;320:1224-9.
21. Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 2003;302:885-9.
22. Zhou Z, Hong EL, Cohen S, Zhao WN, Ho HY, Schmidt L, et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 2006;52:255-69.
23. Chao HT, Zoghbi HY, Rosenmund C. MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron 2007;56:58-65.
24. Nelson ED, Kavalali ET, Monteggia LM. MeCP2-dependent transcriptional repression regulates excitatory neurotransmission. Curr Biol 2006;16:710-6.
25. Patrizi A, Awad PN, Chattopadhyaya B, Li C, Di Cristo G, Fagiolini M. Accelerated hyper-maturation of parvalbumin circuits in the absence of MeCP2. Cereb Cortex 2019 Apr 30 [Epub]. pii: bhz085. https://doi.org/10.1093/cercor/bhz085.
26. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Human Molecular Genetics 2002;11:115-24.
27. Smrt RD, Eaves-Egenes J, Barkho BZ, Santistevan NJ, Zhao C, Aimone JB, et al. Mecp2 deficiency leads to delayed maturation and altered gene expression in hippocampal neurons. Neurobiol Dis 2007;27:77-89.
28. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nature Genetics 1999;23:185-8.
29. Wan M, Lee SS, Zhang X, Houwink-Manville I, Song HR, Amir RE, et al. Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. Am J Hum Genet 1999;65:1520-9.
30. Manavalan A, Mishra M, Feng L, Sze SK, Akatsu H, Heese K. Brain site-specific proteome changes in aging-related dementia. Exp Mol Med 2013;45:e39.
31. Choi J, Kwon HJ, Lee JE, Lee Y, Seoh JY, Han PL. Hyperoxygen-
MeCP2 in Alzheimer Dementia

32. Lin Q, Schwarz J, Bucana C, Olson EN. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 1997;276:1404-7.

33. Lin Q, Lu J, Yanagisawa H, Webb R, Lyons GE, Richardson JA, et al. Requirement of the MADS-box transcription factor MEF2C for vascular development. Development 1998;125:4565-74.

34. Li H, Radford JC, Ragusa MJ, Shea KL, McKercher SR, Zaremba JD, et al. Transcription factor MEF2C influences neural stem/progenitor cell differentiation and maturation in vivo. Proc Natl Acad Sci U S A 2008;105:9397-402.

35. Mao Z, Bonni A, Xia F, Nadal-Vicens M, Greenberg ME. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 1999;286:785-90.

36. Cole CJ, Mercaldo V, Restivo L, Yiu AP, Sekeres MJ, Han JH, et al. MEF2 negatively regulates learning-induced structural plasticity and memory formation. Nat Neurosci 2012;15:1255-64.

37. Le Meur N, Holder-Espinasse M, Jaillard S, Goldenberg A, Joriot S, et al. MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations. J Med Genet 2010;47:22-9.

38. Han K, Gennarino VA, Lee Y, Pang K, Hashimoto-Tori K, Choufani S, et al. Human-specific regulation of MeCP2 levels in fetal brains by microRNA miR-483-5p. Genes Dev 2013;27:485-90.

39. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, et al. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 2010;29:3020-32.

40. Kim M, Suh J, Romano D, Truong MH, Mullin K, Hooli B, et al. Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate [alpha]-secretase activity. Hum Mol Genet 2009;18:3987-96.

41. Suh J, Choi SH, Romano DM, Gannon MA, Lesinski AN, Kim DY, et al. ADAM10 missense mutations potentiate beta-amyloid accumulation by impairing promyloid chaperone function. Neuron 2013;80:385-401.

42. De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurosci 2010;11:699-107.

43. Wang YM, Zheng YF, Yang SY, Yang ZM, Zhang LN, He YQ, et al. MicroRNA-197 controls ADAM10 expression to mediate MeCP2's role in the differentiation of neuronal progenitors. Cell Death Differ 2019;26:1863-79.

44. Long JZ, Svensson KJ, Bateman LA, Lin H, Kamenecka T, Lokurkar IA, et al. The secreted enzyme PM20D1 regulates lipidad amino acid uncouplers of mitochondria. Cell 2016;166:424-35.

45. Sanchez-Mut JV, Heyn H, Silva BA, Dixsaut L, Garcia-Esparcia P, Vidal E, et al. PM20D1 is a quantitative trait locus associated with Alzheimer's disease. Nat Med 2018;24:598-603.

46. Kumar A, Thakur MK. Epigenetic regulation of presenilin 1 and 2 in the cerebral cortex of mice during development. Dev Neurobiol 2015;75:1165-73.

47. Wang C, Wang F, Cao Q, Li Z, Huang L, Chen S. The effect of MeCP2 on heart failure. Cell Physiol Biochem 2018;47:2380-7.

48. Sierant M, Kubiak K, Kazmierczak-Baranska J, Warashina M, Kubara T, Nawrot B. Evaluation of BACE1 silencing in cellular models. Int J Alzheimers Dis 2009;2009. pii: 257403. https://doi.org/10.4061/2009/257403.

49. Bie B, Wu J, Yang H, Xu JJ, Brown DL, Naguib M. Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency. Nat Neurosci 2014;17:223-31.

50. Roux JC, Zala D, Panayotis N, Borgez-Correia A, Saudou F, Villard L. Modification of MeCP2 dosage alters axonal transport through the Huntingtin/Hap1 pathway. Neurobiol Dis 2012;45:786-95.

51. Maphis NM, Jiang S, Binder J, Wright C, Gopalan B, Lamb BT, et al. Whole genome expression analysis in a mouse model of tauopathy identifies MECP2 as a possible regulator of tau pathology. Front Mol Neurosci 2017;10:69. https://doi.org/10.3389/fnmol.2017.00069. eCollection 2017.

52. Montgomery KR, Louis Sam Titus ASC, Wang L, D’Mello SR. Elevated MeCP2 in mice causes neurodegeneration involving tau dysregulation and excitotoxicity: implications for the understanding and treatment of MeCP2 triplication syndrome. Mol Neurobiol 2018;55:9057-74.

53. Hynd MR, Scott HL, Hold D. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem Int 2004;45:583-95.

54. LeBlanc AC. The role of apoptotic pathways in Alzheimer’s disease neurodegeneration and cell death. Curr Alzheimer Rep 2005;2:389-402.

55. Bracaglia G, Conca B, Bergo A, Rusconi L, Zhou Z, Greenberg ME, et al. Methyl-CpG-binding protein 2 is phosphorylated by homeodomain-interacting protein kinase 2 and contributes to apoptosis. EMBO Rep 2009;10:1327-33.

56. Petazzi P, Akizu N, Garcia A, Estaras C, Martinez de Paz A, Rodriguez-Paredes M, et al. An increase in MECP2 dosage impairs neural tube formation. Neurobiol Dis 2014;67:49-56.

57. Tsujimura K, Abematsu M, Kohyama J, Ninomiya H, Nakashima K.
Neuronal differentiation of neural precursor cells is promoted by the methyl-CpG-binding protein MeCP2. Exp Neurol 2009;219:104-11.

58. Dastidar SG, Bardai FH, Ma C, Price V, Rawat V, Verma P, et al. Isoform-specific toxicity of MeCP2 in postmitotic neurons: suppression of neurotoxicity by FoxG1. J Neurosci 2012;32:2846-55.

59. Williams AA, Mehler VJ, Mueller C, Vonhoff F, White R, Duch C. Apoptotic activity of MeCP2 is enhanced by C-terminal truncating mutations. PLoS One 2016;11:e0159632.

60. Russell JC, Blue ME, Johnston MV, Naidu S, Hossain MA. Evidence of decreased growth factor. Life Sci 2016;167:98-104.

61. Jin LW, Horiuchi M, Wulff H, Liu XB, Cortopassi GA, Erickson JD, et al. Dysregulation of glutamate transporter SNAT1 in Rett syndrome microglia: a mechanism for mitochondrial dysfunction and neurotoxicity. J Neurosci 2015;35:2516-29.

62. Ballas N, Lioy DT, Grunseich C, Mandel G. Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nat Neurosci 2009;12:311-7.

63. Roux JC, Dura E, Moncla A, Mancini J, Villard L. Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. Eur J Neurosci 2007;25:1915-22.

64. Roux JC, Panayotis N, Dura E, Villard L. Progressive noradrenergic deficits in the locus coeruleus of Mecp2 deficient mice. J Neurosci Res 2010;88:1500-9.

65. Panayotis N, Pratte M, Borges-Correia A, Ghata A, Villard L, Roux JC. Morphological and functional alterations in the substantia nigra pars compacta of the Mecp2-null mouse. Neurobiol Dis 2011;41:385-97.

66. Palmer A, Qayumi J, Ronnett G. MeCP2 mutation causes distinctive phases of acute and chronic defects in synaptogenesis and maintenance, respectively. Mol Cell Neurosci 2008;37:794-807.

67. Brichta L, Shin W, Jackson-Lewis V, Blesa J, Yap EL, Walker Z, et al. Identification of neurodegenerative factors using translatome-regulatory network analysis. Nat Neurosci 2015;18:1325-33.

68. Gil J. Cellular senescence causes ageing. Nat Rev Mol Cell Biol 2012;2:128-36.

69. Zhang W, Ji W, Yang J, Yang L, Chen W, Zhuang Z. Comparison of global DNA methylation profiles in replicative versus premature senescence. Life Sci 2008;83:475-80.

70. Sanders YY, Liu H, Liu G, Thannickal VJ. Epigenetic mechanisms regulate NADPH oxidase-4 expression in cellular senescence. Free Radic Biol Med 2015;79:197-205.

71. Wang C, Wang J, Li Z, Cao Q, Huang L, Chen S. MeCP2-mediated epigenetic regulation in senescent endothelial progenitor cells. Stem Cell Res Ther 2018;9:87.

72. Ohashi M, Korsakova E, Allen D, Lee P, Fu K, Vargus BS, et al. Loss of MECP2 Leads to Activation of P53 and Neuronal Senescence. Stem Cell Reports 2018;10:1453-63.

73. Squillaro T, Hayek G, Farina E, Cipollaro M, Renieri A, Galderisi U. A case report: bone marrow mesenchymal stem cells from a Rett syndrome patient are prone to senescence and show a lower degree of apoptosis. J Cell Biochem 2008;103:1877-85.

74. Squillaro T, Alessio N, Cipollaro M, Melone MA, Hayek G, Renieri A, et al. Reduced expression of MECP2 affects cell commitment and maintenance in neurons by triggering senescence: new perspective for Rett syndrome. Mol Biol Cell 2012;23:1435-45.

75. Squillaro T, Alessio N, Capasso S, Di Bernardo G, Melone MAB, Peluso G, et al. Senescence phenomena and metabolic alteration in mesenchymal stromal cells from a mouse model of Rett syndrome. Int J Mol Sci 2019;20(10). pii: E2508. https://doi.org/10.3390/ijms2012508.

76. Squillaro T, Alessio N, Cipollaro M, Renieri A, Giordano A, Galderisi U. Partial silencing of methyl cytosine protein binding 2 (MECP2) in mesenchymal stem cells induces senescence with an increase in damaged DNA. FASEB J 2010;24:1593-603.

77. Van Esch H. MECP2 duplication syndrome. Mol Syndromol 2012;2:128-36.

78. Zhee BB, Yaron Y, Schanen NC, Wolf H, Brandt N, Ginot N, et al. Rett syndrome: clinical manifestations in males with MECP2 mutations. J Child Neurol 2002;17:20-4.

79. Ward CS, Huang TW, Herrera JA, Samaco RC, Pitcher MR, Herron A, et al. Loss of MeCP2 causes urological dysfunction and contributes to death by kidney failure in mouse models of Rett syndrome. PLoS One 2016;11:e0165550.

80. Sadegh MK, Ekman M, Krawczyk K, Svensson D, Göransson O, Dahan D, et al. Detrusor induction of miR-132/212 following bladder outlet obstruction: association with MeCP2 repression and cell viability. PLoS One 2015;10:e0116784.

81. Kashyap M, Pore S, Chancellor M, Yoshimura N, Tyagi P. Bladder overactivity involves overexpression of MicroRNA 132 and nerve growth factor. Life Sci 2016;167:98-104.